Skip to main content

Advertisement

Table 1 Reimbursement approval year for indications of 13 anti-cancer drugs in 10 countries (as of February 3, 2013)

From: International comparison of the factors influencing reimbursement of targeted anti-cancer drugs

Drug Indications Countries
Australia Canada (Ontario) France Germany Japan Korea Sweden Taiwan UK US *
Bevacizumab Colorectal cancer : with irinotecan, fluorouracil, and leucovorin No 2009 2005 2009 2007 No No 2011 No 2004
  Colorectal cancer : with oxaliplatin, fluorouracil, and folinic acid 2008 2009 2008 2009 2009 No No No No 2006
  NSCLC : 1st line with platinum-based chemotherapy No No 2008 2009 2009 No No No No 2006
  Renal cell carcinoma : 1st line with interferon-α No No 2008 2009 No No No No No 2009
Cetuximab Colorectal cancer : with irinotecan 2010 2011 2009 2009 2008 No No 2009 No 2004
  Colorectal cancer (K-RAS wild type): 1st line with oxaliplatin, fluorouracil, and folinic acid 2010 No 2009 2009 2010 No No No 2009 2012
  Head and neck cancer (squamous cell carcinoma) : 1st line with platinum-based chemotherapy 2007 2011 2010 No No No No 2009 No 2011
Crizotinib NSCLC (ALK fusion positive): 2nd line (vs. docetaxel) No No No No No No No No No 2011
Dasatinib Chronic myeloid leukemia, chronic phase: 1st line 2009 2008 2007 No 2009 2008 2011 2009 No 2010
Erlotinib Pancreatic cancer : 1st line with gemcitabine 2012 No No No 2011 2010 No No No 2005
Imatinib Gastrointestinal stromal tumor: Adjuvant therapy 2011 2008 2009 No No 2010 2009 2011 no 2008
Lapatinib Breast cancer with HER2 overexpression: 2nd line with capecitabine No No 2008 No 2009 2010 No No No 2007
Lenalidomide Multiple myeloma : 1st-line No 2009 No No 2010 No 2008 No 2009 2006
Nilotinib Chronic myeloid leukemia, chronic phase: 1st-line 2011 2012 2008 2011 2010 2011 2008 2012 2012 2007
Pemetrexed NSCLC: Maintenance treatment No 2008 2008 No 2009 No No No 2010 2009
  NSCLC (for non-squamous histology): 1st line with cisplatin 2009 2008 2008 No 2009 2010 No 2009 2009 2008
Sorafenib Liver cancer : 1st line 2008 2008 2008 2009 2009 2011 No No No 2007
Sunitinib Renal cell carcinoma : 1st line 2010 2008 2006 2009 2008 2007 2006 2010 2009 2006
Temsirolimus Renal cell carcinoma : 1st-line for poor prognosis patients No 2011 2008 2009 2010 2011 No No No 2007
  1. Abbreviations: UK United Kingdom, US United States, NSCLC non-small cell lung cancer.
  2. *For United States, Food and Drug Administration (FDA) approval dates are used. However, the fact that FDA approved a certain cancer drug does not mean that that drug is reimbursed.